SUBSCRIBE
SUBSCRIBE
News   Policy

Biotechnology Industry Organization (BIO) Urges Senate Committee on Finance Not to Limit Patients’ Access to Therapies

April 13, 2007 | 
1 min read
WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) opposes the Chairman’s Mark to the Medicare Prescription Drug Price Negotiation Act of 2007 (S. 3) which is being considered by the Senate Committee on Finance today.
Regulatory
Biotechnology Innovation Organization (BIO)
MORE ON THIS TOPIC
FDA
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
September 9, 2026
 · 
1 min read
 · 
Jef Akst
Balance. A business man maintains a balance between life and work. vector
Regulatory
Acting CBER, CDER heads become permanent as FDA works to restore stability
September 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
September 8, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of businessmen moving a mountain uphill. The men & mountain and background are on separate labeled layers.
Insights
Can Benelux turn scientific strength into larger biotech scale?
September 8, 2026
 · 
4 min read
 · 
Jennifer C. Smith-Parker